Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $10.28 Consensus Target Price from Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average rating of “Hold” by the eleven analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.28.

Several brokerages recently issued reports on MRVI. Wolfe Research assumed coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. The Goldman Sachs Group downgraded shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $7.00 to $4.25 in a report on Thursday, December 5th. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Royal Bank of Canada dropped their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Finally, Guggenheim began coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company.

Insider Activity

In related news, insider Carl Hull bought 175,000 shares of the stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the purchase, the insider now directly owns 175,000 shares of the company’s stock, valued at $987,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.63% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC raised its holdings in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares during the period. JPMorgan Chase & Co. lifted its holdings in Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after purchasing an additional 3,731,924 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Maravai LifeSciences during the third quarter worth about $600,000. Barclays PLC raised its position in shares of Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company’s stock worth $1,531,000 after purchasing an additional 143,184 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in Maravai LifeSciences in the 3rd quarter worth about $136,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $4.93 on Friday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm has a market cap of $1.24 billion, a PE ratio of -3.01 and a beta of -0.07. Maravai LifeSciences has a 12 month low of $4.28 and a 12 month high of $11.56. The stock has a fifty day moving average price of $5.59 and a 200-day moving average price of $7.40.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.